Full Press Release Details
Anavex Life Sciences Reports
Fiscal 2025 Fourth Quarter Financial Results and
Provides Business Update
Company to host a webcast
today at 8:30 a.m. Eastern Time
NEW YORK - November 25, 2025 -
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company
focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental,
neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial
results for its fourth quarter of fiscal 2025.
"There are currently an estimated 7.2 million
people living with Alzheimer's disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted
upstream medicines, particularly in the context of early Alzheimer's disease," said Christopher U. Missling, PhD, President
and CEO of Anavex. "Our clinical pipeline positions Anavex to address critical unmet needs in neurodegenerative and neurodevelopmental
disorders with convenient and scalable therapeutic options. Oral blarcamesine demonstrated continued clinically meaningful benefit in
early-stage Alzheimer's patients-further validating its therapeutic potential. Following the recent announcement the Company
intends to request a re-examination of the CHMP opinion upon its formal adoption, representing our commitment to bring this innovative
medicine to patients in need of new treatment options."
Expected Development Milestones:
Recent Corporate Developments:
ABCLEAR3 = Alzheimer's Blarcamesine Cognition Efficacy and Resilience
gene variants non-carrier population (SIGMAR1 wild type [WT]/COL24A1 wild
Alzheimer's Disease Neuroimaging Initiative (ADNI) is a clinical research
project launched by NIH in 2004 to develop methods to predict the onset and progression of Alzheimer's disease and to confirm the
effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well
as patients with mild cognitive impairment (MCI) and early stages of Alzheimer's disease.
Financial Highlights:
The financial information
for the year ended September 30, 2025, should be read in conjunction with the Company's consolidated financial statements, which
will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com.
Webcast / Conference Call Information:
The live webcast of the conference
call will be available on Anavex's website at www.anavex.com.
The conference call can be also accessed by dialing
1 929 205 6099 for participants in the U.S. using the Meeting ID# 839 7768 4735 and reference passcode 825109. A replay of the conference
call will also be available on Anavex's website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly
traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental,
and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other
central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX 2-73 (blarcamesine),
has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study
in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients
with Rett syndrome. ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1
and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease.
ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating
its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously
awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX 2-73 for the treatment of Parkinson's
disease. We believe that ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX 3-71 has shown beneficial effects on mitochondrial
dysfunction and neuroinflammation. Further information is available at www.anavex.com.
You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that
are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences
Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
| Anavex Life Sciences Corp. |
| Consolidated Statements of Operations and Comprehensive Loss |
| (in thousands, except share and per share amounts) |
| Three months ended September 30, | ||||||||
| 2025 | 2024* | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 3,549 | $ | 2,716 | ||||
| Research and development | 7,295 | 11,555 | ||||||
| Total operating expenses | 10,844 | 14,271 | ||||||
| Operating loss | (10,844 | ) | (14,271 | ) | ||||
| Other income | ||||||||
| Grant income | - | 75 | ||||||
| Research and development incentive income | 13 | 700 | ||||||
| Interest income, net | 1,000 | 1,759 | ||||||
| Foreign exchange gain | 6 | 117 | ||||||
| Total other income, net | 1,019 | 2,651 | ||||||
| Net loss and comprehensive loss | $ | (9,825 | ) | $ | (11,620 | ) | ||
| Net loss per share | ||||||||
| Basic and diluted | $ | (0.11 | ) | $ | (0.14 | ) | ||
| Weighted average number of shares outstanding | ||||||||
| Basic and diluted | 85,893,760 | 84,795,517 |
*Certain immaterial amounts have been reclassified
to conform to the current years' presentation
| Anavex Life Sciences Corp. |
| Consolidated Statements of Operations and Comprehensive Loss |
| (in thousands, except share and per share amounts) |
| Year ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 13,816 | $ | 11,039 | ||||
| Research and development | 37,592 | 41,838 | ||||||
| Total operating expenses | 51,408 | 52,877 | ||||||
| Operating loss | (51,408 | ) | (52,877 | ) | ||||
| Other income (expense) | ||||||||
| Grant income | 37 | 75 | ||||||
| Research and development incentive income | 648 | 2,291 | ||||||
| Interest income, net | 4,678 | 7,320 | ||||||
| Foreign exchange (loss) gain | (332 | ) | 189 | |||||
| Total other income, net | 5,031 | 9,875 | ||||||
| Net loss and comprehensive loss | $ | (46,377 | ) | $ | (43,002 | ) | ||
| Net loss per share | ||||||||
| Basic and diluted | $ | (0.54 | ) | $ | (0.52 | ) | ||
| Weighted average number of shares outstanding | ||||||||
| Basic and diluted | 85,289,447 | 83,468,049 |
| Anavex Life Sciences Corp. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current | ||||||||
| Cash and cash equivalents | $ | 102,577 | $ | 132,187 | ||||
| Incentive and tax receivables | 809 | 2,449 | ||||||
| Prepaid expenses and other current assets | 429 | 931 | ||||||
| Total Assets | $ | 103,815 | $ | 135,567 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 4,249 | $ | 9,627 | ||||
| Accrued liabilities | 3,892 | 4,835 | ||||||
| Deferred grant income | 805 | 842 | ||||||
| Total Liabilities | 8,946 | 15,304 | ||||||
| Capital Stock | 87 | 85 | ||||||
| Additional paid-in capital | 477,230 | 456,249 | ||||||
| Accumulated deficit | (382,448 | ) | (336,071 | ) | ||||
| Total Stockholders' Equity | 94,869 | 120,263 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 103,815 | $ | 135,567 |
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Email: andrew@barwicki.com